(Q35014529)

5 August 2017

1 reference

title

Arimoclomol: a potential therapy under development for ALS. (English)

1 reference

amyotrophic lateral sclerosis

5 August 2017

1 reference

4

Merit Cudkowicz

1 reference

5 August 2017

Veena Lanka

1

1 reference

5 August 2017

Scott Wieland

series ordinal

2

1 reference

5 August 2017

Jack Barber

series ordinal

3

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Expert Opinion on Investigational Drugs

5 August 2017

1 reference

5 August 2017

18

1 reference

5 August 2017

12

1 reference

5 August 2017

1907-1918

1 reference

Amyotrophic lateral sclerosis

5 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

21 January 2018

Motor neurone disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Alsin, the product of ALS2 gene, suppresses SOD1 mutant neurotoxicity through RhoGEF domain by interacting with SOD1 mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Mutant dynactin in motor neuron disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Neuropathy target esterase gene mutations cause motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Low concentrations of glutamate induce apoptosis in cultured neurons: implications for amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Monomeric Cu,Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Protein aggregation in motor neurone disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Mutant Cu/Zn-superoxide dismutase proteins have altered solubility and interact with heat shock/stress proteins in models of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Impairment of the ubiquitin-proteasome system by protein aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Decrease of Hsp25 protein expression precedes degeneration of motoneurons in ALS-SOD1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

21 January 2018

The heat-shock response

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Heat shock proteins delivered with a virus vector can protect cardiac cells against apoptosis as well as against thermal or hypoxic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Upregulation of heat shock proteins rescues motoneurones from axotomy-induced cell death in neonatal rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Venous thrombosis in an ALS population over four years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Controlled trial of nimodipine in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

A clinical trial of verapamil in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Controlled acute trial of a thyrotrophin releasing hormone analogue (RX77368) in motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Evaluation of electrophysiological and clinical tests in an exploratory trial of Org 2766 in motor neuron disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Inosiplex and amyotrophic lateral sclerosis. Therapeutic trial in patients on Guam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Therapeutic trial of tilorone in ALS: Lack of benefit in a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Reversible cognitive decline during high-dose alpha-interferon treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Thalidomide causes sinus bradycardia in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Phase II/III randomized trial of TCH346 in patients with ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903357486

10.1517/13543780903357486

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference